Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines

Leukemia

Volumn 13, Issue 11, 1999, Pages 1864-1872

  Nuessler, V ^a   Stolzer O ^a   Gullis, E ^b   Pelka Fleischer, R ^a   Pogrebniak, A ^b   Gieseler, F ^c   Wilmanns, W ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Apoptosis; Lung resistance protein (LRP); Multidrug resistance (MDR); Multidrug resistance associated protein (MRP); P glycoprotein (P gp)

Indexed keywords

CYTARABINE; CYTOSTATIC AGENT; DACTINOMYCIN; DAUNORUBICIN; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; RHODAMINE 123; VINCRISTINE;

APOPTOSIS; CONFERENCE PAPER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0344614011     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401571     Document Type: Conference Paper

References (57)

1. Kaye SB. Clinical drug resistance: the role of factors other than P-glycoprotein. Am J Med 1995; 99 (Suppl. 6A): S40-S44.
2. Gros P, Neriah YB, Croop JM, Housman DE. Isolation and expression of cDNA (mdr) that confers multidrug resistance. Nature 1986; 323: 728-731.
3. Roninson IB, Chin JE, Choi P, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 4538-4542.
4. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchang KL, Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485-489.
5. Chen C, Chin J, Ueda K. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-389.
6. Ueda K, Cardarelli C, Gottesman M, Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-3008.
7. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-plycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-3815.
8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
9. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993; 60: 157-180.
10. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215
11. Biedler JL. Drug resistance: genotype versus phenotype (Thirty-second CHA Clowes Memorial Award lecture). Cancer Res 1994; 54: 666-678.
12. Hipfner DR, Gauldie SD, Deeley RG, Cole SPC. Detection of the M, 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 1994; 54: 5788-5792.
13. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ, Zaman GJR. Immunochemical detection of the multidrug resistance associated protein MRP in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-4563.
14. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
15. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
16. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Kalk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996; 6: 979-984.
17. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Over-expression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 6: 2464-2469.
18. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995; 1: 578-582.
19. Peters WHM, Roelofs HMJ. Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases. Cancer Res 1992; 52: 1886-1890.
20. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EGE. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992; 52: 6885-6889.
21. Hoa X-Y, Bergh J, Brodin O, Hellman U, Mannervik B. Acquired resistance to cisplatin and doxorubicin in a small lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 1994; 15: 1167-1173.
22. Greenbaum M, Letourneau S, Asar H, Schecter RL, Batist G, Cournoyer D. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res 1994; 54: 4442-4447.
23. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1995; 54: 4313-4320.
24. O'Dwyer PJ, Hamilton TC, Yao K-S, Tew KD, Ozols RF. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol Oncol Clin North Am 1995; 9: 383-396.
25. Preisler HD. Resistance to cytotoxic therapy: a speculative overview. Ann Oncol 1995; 6: 651-657.
26. Reed JC, Miyashita T, Cuddy M, Cho D. Regulation of p26-Bcl-2 protein levels in human peripheral blood lymphocytes. Am J Pathol 1992; 67: 443-449.
27. Delia D, Arello A, Soligo D, Fontanella E, Melani C, Pezzalla F, Pierotti M, Della Porta G. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 79: 1291-1298.
28. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996; 10: 3987-3997.
29. Lohri A, van Hille B, Reuter J, Tichelli A, Herrmann R. mRNA expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukemic peripheral blood and bone marrow. Acta Haematol 1997; 98: 1-7.
30. Barge RMY, Willemze R, Vandenabeele P, Fiers W, Beyaert R. Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal. FEBS Lett 1997; 409: 207-210.
31. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997; 11: 253-257.
32. Grillier I, Umiel T, Elstner E, Collins SJ, Koeffler HP. Alterations of differentation, clonal proliferation, cell cycle progression and bcl-2 expression in RARa-altered sublines of HL-60. Leukemia 1997; 11: 393-400.
33. Ibrado AM, Liu L, Bhalla K. Bcl-xl overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1997; 57: 1109-1115.
34. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xl inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996; 56: 4743-4748.
35. Porwit-Macdonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 proteins expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995; 9: 1191-1198.
36. Salomons GS, HJM Brady, Verwus-Janssen M, van den Berg JD, Hart AAM, van den Berg H, Behrendt H, Hählen K, Smets LA. The Baxa:Bcl-2 ratio modulates the response to dexamethasone in leukemic cells and is highly variable in childhood acute leukemia, Int J Cancer 1997; 71: 959-965.
37. Buske C, Becker D, Feuring-Buske, Hannig H, Wulf G, Schäfer C, Hiddemann W, Wörmann B. TGF-βinhibits growth and induces apoptosis in leukemic B cell precursors. Leukemia 1997; 11: 386-392.
38. Uckun FM, Zhiwen Y, Sather H, Steinherz P, Nachmann J, Bostrom B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P. Cellular expression of antiapoptotic Bcl-2 oncoprotein in newly diagnosed childhood acute lymphoblatic leukemia: a Children's Cancer Group study. Blood 1997; 10: 3769-3777.
39. Tani A, Tatsumi E, Nakamura F, Kumagai S, Kosaka Y, Sano K, Nakamura H, Amakawa R, Ohno H. Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines. Leukemia 1996; 10: 1592-1603.
40. Palumbo GA, Yarom N, Gazit A, Sandalon Z, Baniyash M, Kleinberger-Doron N, Levitzki A, Ben-Yehuda D. The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res 1997; 57: 2434-2439.
41. Yang-ja L, Shacter E. Bcl-2 does not protect Burkett's lymphoma cells from oxidant-induced cell death. Blood 1997; 89: 4480-4492.
42. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell 1993; 74: 609-619.
43. Williams GT, Smith C. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-779.
44. Krajewski S, Krajewski M, Shabaik A, Miyashita T, Wang HG. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-1326.
45. Boise LH, Gonzalez-Garcia M, Postena CE, Ding L, Lindstren T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
46. Schlaifer D, Marck M, Krajewski S, Laurent G, Pris J, Delsol G, Reed JC. High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood 1995; 85: 2671-2674.
47. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995; 55: 2262-2265.
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation in cytotoxicity assays. J Immunol Meth 1981; 65: 55-63.
49. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazloium-based semiautomated colorimetric assay, assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
50. Nüssler V, Gullis E, Pelka-Fleischer R, del Valle F, Diem H, Beyerlein S, Zwierzina H, Wilmanns W. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients. Ann Hematol 1997; 75: 17-26.
51. Maslak P, Hegewisch-Becker S, Godfrey I, Andreeff M. Flow-cytometric determination of the multidrug resistant phenotype in acute leukemia. Cytometry 1994; 17: 84-93.
52. Hockenbery D, Nunez G, Milliman C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
53. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
54. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
55. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CA. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995; 184: 39-51.
56. Pallis M, Zhu YM, Russell NH. Bcl-xl is heterogeneously expressed by acute myeloblastic leukemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 1997; 11: 945-949.
57. Datta R, Manome Y, Taneja N. Overexpression of bcl-xl by cytotoxic drug exposure confers resistance to ionising radiation-induced internucleosomal DNA fragmentation. Cell Growth Diff 1995; 6: 363-370.